Boehringer Ingelheim
This study is open for adults with advanced cancer (solid tumours). This is a study for people for whom previous treatment was not successful. This study tests a medicine called BI 907828. BI 907828 is a so-called MDM2 inhibitor that is being developed to treat cancer. The purpose of this study is to find out whether the amount of BI 907828 in the blood is influenced by taking an OATP inhibitor or a CYP3 inhibitor. This study uses an OATP inhibitor called rifampicin and a CYP3 inhibitor called itraconazole. In clinical practice, rifampicin is used as an antibiotic. Itraconazole is used to treat fungal infections. Participants are divided into 2 groups: a rifampicin group and an itraconazole group. Every participant takes BI 907828 as a tablet every 3 weeks. This is called a cycle. Rifampicin group: In addition to BI 907828, participants take 1 tablet of rifampicin in the second cycle. Itraconazole group: In addition to BI 907828, participants take itraconazole tablets for 20 days starting 1 week after the second cycle begins Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors take blood samples from the participants to compare the amount of BI 907828 in the blood when it is taken alone and when participants also take rifampicin. Doctors also regularly check participants' health and take note of any unwanted effects.
Solid Tumors
BI 907828
Rifampicin
Itraconazole
Phase 1
Study Type : | Interventional |
Estimated Enrollment : | 32 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction When BI 907828 is Co-administered With an OATP1B1 and/or OATP1B3 Transporter Inhibitor or With a CYP3A4 Inhibitor in Patients With Various Solid Tumours |
Actual Study Start Date : | June 30, 2022 |
Estimated Primary Completion Date : | August 31, 2024 |
Estimated Study Completion Date : | June 30, 2025 |
Arm | Intervention/treatment |
---|---|
Experimental: Group 1: OATP1B1/B3 inhibitor |
Comrade: BI 907828 Drug: Rifampicin |
Experimental: Group 2: CYP3A4 inhibitor |
Comrade: BI 907828 Drug: Itraconazole |
Ages Eligible for Study: | 18 Years to 70 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Brussels - UNIV Saint-Luc
Bruxelles, Belgium, 1200
Recruiting
Wilrijk - HOSP GZA (St-Augustinus)
Wilrijk, Belgium, 2610
Recruiting
Chiron Hospital. I.C.U.
Barcelona, Spain, 08023
Recruiting
Hebron Valley Hospital
Barcelona, Spain, 08035
Recruiting
Jiménez Díaz Foundation
Madrid, Spain, 28040
Recruiting
CIO Clara Campal
Madrid, Spain, 28050
Recruiting
Quirónsalud Hospital Madrid
Madrid, Spain, 28223